finanzen.net

CCYC

Seite 1 von 5
neuester Beitrag: 20.12.18 15:01
eröffnet am: 13.01.09 13:17 von: _bbb_ Anzahl Beiträge: 112
neuester Beitrag: 20.12.18 15:01 von: Bayernland1 Leser gesamt: 23981
davon Heute: 5
bewertet mit 3 Sternen

Seite: 1 | 2 | 3 | 4 | 5 | 5   

13.01.09 13:17
3

5662 Postings, 4350 Tage _bbb_CCYC

Press Release Source: Cyclacel Pharmaceuticals, Inc.


Cyclacel Begins Phase 2 Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
Tuesday January 13, 7:00 am ET


BERKELEY HEIGHTS, N.J., Jan. 13, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NasdaqGM:CYCC - News) (NasdaqCM:CYCCP - News) announced today that the company has begun treating patients in a Phase 2, open label, single arm, multicenter clinical trial of sapacitabine (CYC682) in patients with non-small cell lung cancer (NSCLC) who have had one prior chemotherapy. This study builds on the observation of prolonged stable disease of four months or longer experienced by heavily pretreated NSCLC patients involved in two Phase 1 studies of sapacitabine. The multicenter Phase 2 trial is led by Philip D. Bonomi, M.D., the Alice Pirie Wirtz Professor of Medical Oncology at the Rush University Medical Center, Chicago.
ADVERTISEMENT


``Nucleoside analogs, such as gemcitabine, have significant activity in NSCLC,'' said Dr. Bonomi. ``We are interested in evaluating sapacitabine because of its unique mechanisms of action, indication of activity in Phase 1 studies and the possibility that it may be an active drug in NSCLC that can be administered by the oral route.''

The primary objective of the study is to evaluate the rate of response and stable disease in patients with previously treated NSCLC. Secondary objectives are to assess progression-free survival, duration of response, duration of stable disease, one year survival, overall survival and safety. The study will enroll approximately 60 patients and has a lead-in phase for dose escalation with the objective of defining a recommended dose followed by a second stage in which patients will be treated at the recommended dose. Study completion is planned to occur approximately six months after the last patient is enrolled.

``The opening of this study marks the expansion of the Phase 2 program of sapacitabine into solid tumors,'' said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. ``We believe that sapacitabine has the potential to emerge as a novel, orally administered treatment for patients with both hematologic malignancies and solid tumors. During this quarter Cyclacel will meet with the U.S. FDA to discuss registration pathways for sapacitabine as a treatment for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) in elderly patients.''

About Sapacitabine

Cyclacel is now evaluating sapacitabine, an orally available nucleoside analog, in three Phase 2 trials in both hematological and solid tumors. Sapacitabine acts through a dual mechanism, interfering with DNA synthesis by causing single-strand DNA breaks and inducing arrest of cell cycle progression mainly at G2/M-Phase. Both sapacitabine and CNDAC, its major metabolite, have demonstrated potent anti-tumor activity in preclinical studies. Sapacitabine has been given as a single agent to approximately 170 patients with both hematologic malignancies and solid tumors in four Phase 1 studies. In Phase 1 trials reported earlier sapacitabine was evaluated in 47 pretreated patients with advanced leukemias or MDS and 123 heavily pretreated patients with various solid tumors. In the hematological malignancy trial six patients achieved complete remission or complete remission without platelet count recovery and a further 15 had a significant decrease in bone marrow blasts including 7 with blast reduction to 5% or less. In the solid tumor studies, 20 patients experienced prolonged stable disease and remained on study for four months or longer, five with NSCLC, one with small cell lung cancer, four with colorectal, two with bladder, two with gastrointestinal stromal tumors, two with ovarian, one with breast, one with renal, one with parotid and one with an unknown primary tumor. Sapacitabine is also being studied in a currently ongoing Phase 2 trial in patients with advanced cutaneous T cell lymphoma.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes, cutaneous T-cell lymphoma and lung cancer. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. Several additional programs are at an earlier stage. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair(R) Cream for radiation dermatitis, Numoisyn(TM) Liquid and Numoisyn(TM) Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology, oncology and other therapeutic areas based on a portfolio of commercial products and a development pipeline of novel drug candidates.

Please visit http://www.cyclacel.com for additional information. Note: The Cyclacel logo and Cyclacel(R) are trademarks of Cyclacel Pharmaceuticals, Inc.; Numoisyn(TM) and Xclair(R) are trademarks of Sinclair Pharma plc.

Risk Factors

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words ``may,'' ``will,'' ``would,'' ``could,'' ``should,'' ``believes,'' ``estimates,'' ``projects,'' ``potential,'' ``expects,'' ``plans,'' ``anticipates,'' ``intends,'' ``continues,'' ``forecast,'' ``designed,'' ``goal,'' or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under ``Risk Factors'' in the Annual Report on Form 10-K for the year ended December 31, 2007, as supplemented by the interim quarterly reports, filed with the SEC.



Contact:
         Cyclacel Pharmaceuticals, Inc.
         Corey Sohmer
         (908) 517-7330

         WeissComm Partners
         Aline Schimmel
         (312) 646-6295

         College Hill, Life Sciences
         Sue Charles
         Justine Lamond
         +44 (20) 7866 7857


--------------------------------------------------
Source: Cyclacel Pharmaceuticals, Inc.  
Seite: 1 | 2 | 3 | 4 | 5 | 5   
86 Postings ausgeblendet.

22.09.17 15:06

16540 Postings, 3425 Tage Balu4uAsk erstmal runter, bin gespannt

auf den heutigen Handelstag. Sollte schon über 2 USD bleiben! Dann schauen wir nächste Woche mal weiter...  

22.09.17 19:02

2303 Postings, 3407 Tage Schokoriegelwas kann man von den letzten 3 Tagen halten?

war das bloß ein kurzer Zock oder eher heute durch den Rückgang eine Ausbruchsbestätigung? eigentlich wäre jetzt noch mal die Chance zum einsteigen, oder?  

22.09.17 20:10
1

233 Postings, 898 Tage AndrolytIch

habe gesternzum Handelsende verkauft und heute wieder nachgekauft.War etwas überrascht heute über den starken Rückgang.Wenn man Jahreshoch und Jahrestief sich anschaut erübrigt sich die Frage ob das Kaufkurse sind auf aktuellem Niveau..  

25.09.17 17:10

233 Postings, 898 Tage Androlyt16.52 ein netter Sprung

mal schauen wie es die Woche weitergeht..  

02.10.17 23:23

233 Postings, 898 Tage AndrolytSowas wie

bei Endocyte kann hier auch jeder Zeit passieren mit den richtigen Nachrichten..  

06.10.17 00:24

233 Postings, 898 Tage AndrolytAnlaufschwierigkeiten

wenns knallt stehen wir ganz wo anders..Celsion und Endocyt haben den Drecksshorties gezeigt wie schnell sich das Ganze drehen kann..  

06.10.17 15:15

112 Postings, 3483 Tage BohnebeitelWelche Nachrichten führten endocyt aus dem Sumpf?

16.10.17 17:06

233 Postings, 898 Tage AndrolytBald

knallts hier..Die Vorboten sind klar zu erkennen..  

27.10.17 14:41

112 Postings, 3483 Tage BohnebeitelGestern hat's geknallt. Oh weia..

27.10.17 14:41

112 Postings, 3483 Tage BohnebeitelSch... Autokorrektur.

27.10.17 15:12

233 Postings, 898 Tage AndrolytDamit

hätte ich nicht gerechnet,ohne News so ein Abgang..Macht leider momentan kein Spass mehr..  

01.11.17 15:17

233 Postings, 898 Tage AndrolytNicht zu fassen

was aus 10% Plus übrig geblieben ist..einfach nur schäbig..  

02.11.17 15:09

233 Postings, 898 Tage AndrolytHab mich

heute getrennt von diesem Wert.. Allen trotzdem viel Erfolg..  

04.12.17 21:36

16540 Postings, 3425 Tage Balu4u$2.19 * 0.22 11.17%

05.12.17 22:13

233 Postings, 898 Tage AndrolytHier wird

vor den Daten am Montag ordentlich manipuliert,absolut sinnloser Absturz Heute  

12.12.17 14:16

233 Postings, 898 Tage AndrolytBleibt eine

elende Schrottaktie..  

05.09.18 19:50

16540 Postings, 3425 Tage Balu4uErste Ausbruchversuche und höchtes Volumen

20.12.18 12:24

3970 Postings, 802 Tage VassagoCYCC 0,695$ (-6%)

  • MK 9 Mio. $

  • Cash 19 Mio. $
 

20.12.18 15:01

22 Postings, 3497 Tage Bayernland1???

Was stimmt da nicht ß Ist die Pipeline Schrott ?  

Seite: 1 | 2 | 3 | 4 | 5 | 5   
   Antwort einfügen - nach oben

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Braas Monier Building Group S.A.BMSA01
MTU Aero Engines AG Em 2017A2G83P
Deutsche Bank AG514000
Daimler AG710000
Wirecard AG747206
Microsoft Corp.870747
Apple Inc.865985
Amazon906866
Barrick Gold Corp.870450
CommerzbankCBK100
Allianz840400
Scout24 AGA12DM8
BASFBASF11
EVOTEC SE566480
TeslaA1CX3T